Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection

NCT02842086 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

5399

Enrollment

INDUSTRY

Sponsor class

Conditions

Pre-Exposure Prophylaxis of HIV-1 Infection

Interventions

DRUG: F/TAF
DRUG: F/TDF
DRUG: F/TAF Placebo
DRUG: F/TDF Placebo

Sponsor

Gilead Sciences